Table 3.

Kaplan Meier survival estimates for overall survival and disease-free survival

Factor	n event/n total	5 yr OS† rate (%) (±SD)	p	n event/n total	5 yr DFS¥ rate (%) (±SD)	p
Age
<50	2/28	88 (7.5)	0.324	8/28	66.4 (9.8)	0.756
>50	36/288	84 (2.7)		67/288	72.0 (3.2)
Family history
(+)	1/34	97.4 (2.6)	0.050	6/34	79.4 (7.7)	0.195
(−)	37/282	82.9 (2.8)		69/282	70.6 (3.3)
Menopause status
premenopausal	14/154	89 (3.0)	0.336	42/154	69.1 (4.4)	0.309
postmenopausal	19/162	85.5 (3.4)		29/162	74.3 (4.4)
Pathological stage
Stage 1	4/84	95.5 (2.6)	0.017	12/84	80.4 (5.5)	0.021
Stage 2&3	34/232	80.7 (3.4)		63/232	68.4 (3.6)
Histological grade
Grade 1&2	8/76	81.7 (6.3)	0.256	18/76	68.4 (6.6)	0.515
Grade 3	27/200	82.9 (3.3)		48/200	70.9 (3.9)
Tumor stage
T1&T2	27/280	88.5 (2.4)	0.001	52/280	76.3 (3.1)	<0.001
T3&T4	9/36	61.1 (10.4)		20/36	39.4 (9.5)
Nodal positivity
node (−)	14/163	88.8 (3.0)	0.07	27/163	79.4 (3.8)	0.006
node (+)	23/153	81 (4.0)		45/153	64.4 (4.7)
Extensive nodal involvement
positive node≤ 10	29/293	87.2 (2.5)	<0.001	60/293	74.9 (3.0)	<0.001
positive node>10	8/23	58.7 (11.6)		12/23	41 (12.7)
Tumor size
≤2 cm	9/128	93.7 (2.5)	0.038	20/128	77.3 (4.8)	0.01
>2 cm	27/188	81.4 (3.4)		52/188	68.4 (4.0)
Locally advanced disease
(−)	16/177	88.4 (3.0)	0.063	29/177	78.7	0.001
(+)	22/139	79.7 (4.2)		46/139	63.1
Site of progression
Locoregional	3/22	88.4 (3.0)	0.003	22/22	9.1 (1.1)	0.572
Distant metastases	32/55	79.7 (4.2)		55/55	5.7 (3.2)
Taxane regimens*
(+)	6/40	72.1 (10.2)	0.157	13/40	59.3 (9.9)	0.068
(−)	16/113	83.4 (4.4)		31/113	65.5 (5.4)
Type of operation
Mastectomy	26/178	82.0 (3.5)	0.181	52/178	67.8 (4.1)	0.031
Breast conserving	12/138	88.6 (3.3)		23/138	77.1 (4.4)

Among node (+) patients.

^†OS: Overall survival

^¥DFS: Disease-free survival